Alignment Healthcare, Inc. ALHC
6 trading plans running, 49 Form 144 notices for $317.9M
10-Q, 10-K and Form 144What ALHC's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Mar 12, 2025 to Jun 30, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| John Kao Chairman and Chief Executive Officer(2) |
Adopted 10b5-1 plan | May 27, 2026 | 10-Q Jul 30, 2026 | ||
| Dawn Maroney President |
Adopted 10b5-1 plan | Mar 13, 2026 | 10-Q Apr 30, 2026 | ||
| Hyong (Ken) Kim, M.D. Chief Medical Officer |
Adopted 10b5-1 plan | Mar 13, 2026 | 10-Q Apr 30, 2026 | ||
| Sebastian Burzacchi Chief Operating Officer - MSO |
Adopted 10b5-1 plan | Mar 13, 2026 | 10-Q Apr 30, 2026 | ||
| Joseph Konowiecki Chairman of the Board |
Adopted 10b5-1 plan | Mar 4, 2026 | 10-Q Apr 30, 2026 | ||
| Andreas Wagner Chief Human Resources Officer |
Adopted 10b5-1 plan | Nov 21, 2025 | 10-K Feb 27, 2026 | ||
| John Kao Chief Executive Officer |
Adopted 10b5-1 plan | Nov 21, 2025 | 10-K Feb 27, 2026 | ||
| Christopher Joyce Chief Legal & Administrative Officer |
Adopted 10b5-1 plan | Sep 8, 2025 | 10-Q Oct 30, 2025 | ||
What the company wroteDuring the fiscal quarter ended September 30, 2025, our executive officers and directors adopted or terminated, as applicable, the following trading arrangements that are intended to satisfy the affirmative defense of Rule 10b5-1(c): Name & Title Date of Adoption Date of Termination Duration of Trading Arrangement Maximum Number of Securities to be Sold (1) Christopher Joyce, Chief Legal & Administrative Officer 9/8/2025 N/A 12/8/2025 – 9/11/2026 95,455 (1) Securities reported in this column include securities subject to limit orders and such orders may not fill if limit order conditions are not met. The actual number of shares sold under the plan will depend on the vesting of certain performance-based equity awards and the number of shares withheld or sold satisfy our income tax withholding obligations and may vary from the number provided herein. The number of performance share units included in plans assumes awards are earned at target. | |||||
| Dawn Maroney President |
Adopted 10b5-1 plan | May 22, 2025 | 10-Q Jul 30, 2025 | ||
What the company wroteDuring the fiscal quarter ended June 30, 2025, our executive officers and directors adopted or terminated, as applicable, the following trading arrangements that are intended to satisfy the affirmative defense of Rule 10b5-1(c): Name & Title Date of Adoption Date of Termination Duration of Trading Arrangement Maximum Number of Securities to be Sold (1) Dawn Maroney, President 5/22/2025 N/A 8/25/2025 – 6/30/2026 410,000 (1) Securities reported in this column include securities subject to limit orders and such orders may not fill if limit order conditions are not met. The actual number of shares sold under the plan will depend on the vesting of certain performance-based equity awards and the number of shares withheld or sold satisfy our income tax withholding obligations and may vary from the number provided herein. The number of performance share units included in plans assumes awards are earned at target. | |||||
| Thomas Freeman Chief Financial Officer |
Ended 10b5-1 plan | Mar 14, 2025 | 10-Q May 1, 2025 | ||
| John Kao Chief Executive Officer |
Adopted 10b5-1 plan | Mar 12, 2025 | 10-Q May 1, 2025 | ||
| Andreas Wagner Chief Human Resources Officer |
Adopted 10b5-1 plan | Mar 11, 2025 | 10-Q May 1, 2025 | ||
| Christopher Joyce Chief Legal & Administrative Officer |
Adopted 10b5-1 plan | Nov 27, 2024 | 10-K Feb 27, 2025 | ||
| Dawn Maroney President |
Adopted 10b5-1 plan | Nov 25, 2024 | 10-K Feb 27, 2025 | ||
| Thomas Freeman Chief Financial Officer |
Ended 10b5-1 plan | Nov 20, 2024 | 10-K Feb 27, 2025 | ||
| Hyong (Ken) Kim, M.D. Chief Medical Officer |
Adopted 10b5-1 plan | Sep 5, 2024 | 10-Q Oct 29, 2024 | ||
What the company wroteDuring the fiscal quarter ended September 30, 2024, our executive officers and directors adopted the following trading arrangements that are intended to satisfy the affirmative defense of Rule 10b5-1(c): Name & Title Date of Adoption Duration of Trading Arrangement Maximum Number of Securities to be Sold (1) Hyong (Ken) Kim, M.D. Chief Medical Officer 09/05/2024 12/5/2024 - 8/8/2025 145,034 (1) Securities reported in this column include securities subject to limit orders and such orders may not fill if limit order conditions are not met. | |||||
| Christopher Joyce Chief Legal & Administrative Officer |
Adopted 10b5-1 plan | Mar 15, 2024 | 10-Q May 2, 2024 | ||
| Jeffrey Margolis Director |
Adopted 10b5-1 plan | Mar 15, 2024 | 10-Q May 2, 2024 | ||
| Thomas Freeman Chief Financial Officer |
Adopted 10b5-1 plan | Mar 15, 2024 | 10-Q May 2, 2024 | ||
| Hakan Kardes Chief Experience Officer |
Adopted 10b5-1 plan | Mar 14, 2024 | 10-Q May 2, 2024 | ||
| Hyong (Ken) Kim, M.D. Chief Medical Officer |
Adopted 10b5-1 plan | Mar 14, 2024 | 10-Q May 1, 2025 | ||
| John Kao Chief Executive Officer |
Adopted 10b5-1 plan | Mar 14, 2024 | 10-Q May 2, 2024 | ||
| Robert Scavo Chief Information Officer |
Adopted 10b5-1 plan | Mar 14, 2024 | 10-Q May 1, 2025 | ||
| Dawn Maroney President, Markets |
Adopted 10b5-1 plan | Mar 13, 2024 | 10-Q May 2, 2024 | ||
Show the other 16 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 4, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 9, 2026 | Joseph Konowiecki Chairman / EVP, Corporate Affairs |
5,500 | $40K |
| Oct 5, 2026 | Hyong (Ken) Kim, M.D. Chief Medical Officer |
36,000 | $305K |
| Sep 16, 2026 | Joseph Konowiecki Director / EVP, Corporate Affairs |
26,000 | $226K |
| Sep 10, 2026 | JEK TRUST U/A DTD 02/08/2021 Director, Officer |
500,000 | $6.5M |
| Sep 9, 2026 | Dawn C. Maroney President |
130,000 | $1.7M |
| Sep 9, 2026 | John Kao Chief Executive Officer / Director |
405,000 | $5.3M |
| Aug 14, 2026 | DAWN MARONEY Officer |
5,000 | $67K |
| Jul 15, 2026 | DAWN MARONEY Officer |
177,068 | $3.8M |
| Jul 10, 2026 | JEK TRUST U/A DTD 02/08/2021 Director, Officer |
596,000 | $12.5M |
| Jul 1, 2026 | Joseph Konowiecki Director |
25,000 | $600K |
| Jun 26, 2026 | Joseph Konowiecki Director |
25,000 | $575K |
| Jun 18, 2026 | Joseph Konowiecki Director |
25,000 | $550K |
| Jun 12, 2026 | HYONG J KIM Officer |
35,951 | $728K |
| Jun 12, 2026 | SEBASTIAN BURZACCHI Officer |
1,142 | $23K |
| Jun 11, 2026 | Joseph Konowiecki Director |
25,000 | $525K |
| May 11, 2026 | JEK TRUST U/A DTD 02/08/2021 Director, Officer |
596,000 | $10.7M |
| Apr 15, 2026 | DAWN MARONEY Officer |
90,000 | $1.9M |
| Apr 7, 2026 | JEK TRUST U/A DTD 02/08/2021 Director, Officer |
548,000 | $10.2M |
| Apr 6, 2026 | James M. Head Chief Financial Officer |
12,000 | $224K |
| Apr 1, 2026 | Christopher Joyce Officer |
18,013 | $317K |
| Mar 23, 2026 | JEK TRUST U/A DTD 02/08/2021 Director, Officer |
118,000 | $2.0M |
| Mar 19, 2026 | ANDREAS WAGNER Officer |
11,602 | $211K |
| Mar 16, 2026 | Hyong (Ken) Kim, M.D. Chief Medical Officer |
38,762 | $659K |
| Mar 16, 2026 | Sebastian Burzacchi Chief Operating Officer - MSO |
16,987 | $289K |
| Mar 16, 2026 | Christopher Joyce Chief Legal & Administrative Officer |
27,592 | $469K |
| Mar 16, 2026 | Dawn C. Maroney President |
40,643 | $691K |
| Mar 16, 2026 | John Kao Chief Executive Officer |
80,788 | $1.4M |
| Mar 16, 2026 | Andreas P. Wagner Chief Human Resources Officer |
13,271 | $225K |
| Mar 16, 2026 | Robert L. Scavo Chief Information Officer |
12,145 | $206K |
| Mar 10, 2026 | JEK TRUST U/A DTD 02/08/2021 Director, Officer |
180,000 | $3.3M |
| Mar 10, 2026 | Robert L. Scavo Chief Information Officer |
4,100 | $76K |
| Mar 10, 2026 | Dawn Maroney President |
30,000 | $553K |
| Mar 10, 2026 | John Kao Chief Executive Officer |
50,000 | $922K |
| Mar 4, 2026 | ANDREAS WAGNER Officer |
21,118 | $390K |
| Feb 9, 2026 | Andreas Wagner Chief Human Resources Officer |
22,500 | $489K |
| Jan 6, 2026 | DAWN MARONEY Officer |
318,152 | $6.7M |
| Jan 6, 2026 | HYONG J KIM Officer |
16,506 | $347K |
| Dec 23, 2025 | Robert Scavo Chief Information Officer |
68,000 | $1.4M |
| Dec 23, 2025 | Christopher Joyce Chief Legal & Admin. Officer |
15,000 | $303K |
| Dec 23, 2025 | Dawn Maroney President |
275,000 | $5.6M |
| Dec 23, 2025 | John Kao Chief Executive Officer |
600,000 | $12.1M |
| Dec 23, 2025 | Hyong (Ken) Kim, M.D. Chief Medical Officer |
13,000 | $262K |
| Dec 15, 2025 | DAWN MARONEY Officer |
213,319 | $4.1M |
| Dec 12, 2025 | DAWN MARONEY Officer |
16,681 | $324K |
| Dec 11, 2025 | Sebastian Burzacchi Chief Operating Officer - MSO |
12,585 | $242K |
| Dec 10, 2025 | JEK TRUST U/A DTD 02/08/2021 Director, Officer |
540,000 | $10.4M |
| Dec 10, 2025 | General Atlantic (ALN HLTH), L.P. Affiliate |
11,119,494 | $206.5M |
| Dec 8, 2025 | CHRISTOPHER J. JOYCE Officer |
30,317 | $593K |
| Nov 25, 2025 | Joseph Konowiecki Director |
25,000 | $475K |
Show the other 41 notices
From the Form 144 XML filed with the SEC, since Nov 25, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALHC/export.csv") into a cell.